These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 6931828)

  • 1. Studies on aclacinomycin A resistance in mouse lymphoblastoma.
    Nishimura T; Suzuki H; Muto K; Tanaka Y; Tanaka N
    J Antibiot (Tokyo); 1980 Jul; 33(7):737-43. PubMed ID: 6931828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolation, drug sensitivity, and some biochemical and genetical properties of macromomycin-resistant mouse lymphoblastoma L5178Y cells.
    Suzuki H; Sugimoto Y; Tanaka K; Nishimura T; Tanaka N
    J Antibiot (Tokyo); 1984 May; 37(5):602-9. PubMed ID: 6547433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experimental studies of new anthracyclines: aclacinomycin, THP-adriamycin and ditrisarubicins.
    Umezawa K; Kunimoto S; Takeuchi T
    Biomed Pharmacother; 1987; 41(5):206-13. PubMed ID: 2444279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of action of 2-crotonyloxymethyl-4,5,6-trihydroxycyclohex-2-enone, a SH inhibitory antitumor antibiotic, and its effect on drug-resistant neoplastic cells.
    Sugimoto Y; Suzuki H; Yamaki H; Nishimura T; Tanaka N
    J Antibiot (Tokyo); 1982 Sep; 35(9):1222-30. PubMed ID: 7142023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Study of new antineoplastic antibiotics based on newly discovered action mechanisms].
    Tanaka N
    Gan To Kagaku Ryoho; 1983 Apr; 10(4 Pt 2):1094-106. PubMed ID: 6191673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Studies on the mechanism of drug resistance in tumor cells and a new antitumor antibiotic].
    Tanaka N
    Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2666-73. PubMed ID: 6210060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of adriamycin resistance in a subline of mouse lymphoblastoma L5178Y cells.
    Nishimura T; Suzuki H; Muto K; Tanaka N
    J Antibiot (Tokyo); 1979 May; 32(5):518-22. PubMed ID: 583339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alteration of membrane-associated enzymes in drug-resistant sublines of mouse lymphoblastoma L5178Y cells.
    Sugimoto Y; Nishimura T; Suzuki H; Tanaka N
    J Antibiot (Tokyo); 1981 Sep; 34(9):1200-5. PubMed ID: 6173369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potentiation of adriamycin accumulation and effectiveness in adriamycin-resistant cells by aclacinomycin A.
    Tapiero H; Boulé D; Trincal G; Fourcade A; Lampidis TJ
    Leuk Res; 1988; 12(5):411-8. PubMed ID: 3164087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of amino acid uptake and incorporation into proteins in Friend erythroleukemia cells by the anthracycline antitumor antibiotic aclacinomycin A.
    Schaefer A; Boldt J; Westendorf J; Steinheider G; Marquardt H
    Biochem Pharmacol; 1988 Apr; 37(7):1377-82. PubMed ID: 3162677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid uptake by cultured tumor cells and intracellular behavior of 4'-O-tetrahydropyranyladriamycin.
    Kunimoto S; Miura K; Takahashi Y; Takeuchi T; Umezawa H
    J Antibiot (Tokyo); 1983 Mar; 36(3):312-7. PubMed ID: 6833151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative nuclear and cellular incorporation of daunorubicin, doxorubicin, carminomycin, marcellomycin, aclacinomycin A and AD 32 in daunorubicin-sensitive and -resistant Ehrlich ascites in vitro.
    Seeber S; Loth H; Crooke ST
    J Cancer Res Clin Oncol; 1980; 98(2):109-18. PubMed ID: 6938517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of anthracycline analogues on the appearance of newly synthesized total RNA and messenger RNA in the cytoplasm of erythroleukemia cells.
    Long BH; Willis CE; Prestayko AW; Crooke ST
    Mol Pharmacol; 1982 Jul; 22(1):152-7. PubMed ID: 6956804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent studies on antibiotics and small molecular immunomodulators with potential usefulness in treating lung cancer: Part I - Antitumor antibiotics and their derivatives.
    Umezawa H
    Int J Clin Pharmacol Ther Toxicol; 1982 Jan; 20(1):12-8. PubMed ID: 6173340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transplantability and sensitivity to natural killer cells of aclarubicin-resistant murine lymphoma.
    Sugimoto Y; Hirakawa Y; Tanaka N; Tahara M; Sato I; Nishimura T; Suzuki H; Tanaka N
    Cancer Res; 1986 Nov; 46(11):5646-8. PubMed ID: 3463416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence of multifactorial mechanisms in an adriamycin-resistant HL-60 promyelocytic leukemia cell line.
    Burres NS; Myers MT; Sartorelli AC
    Cancer Biochem Biophys; 1988 Jul; 10(1):47-57. PubMed ID: 3224331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uptake and retention of adriamycin and daunorubicin by sensitive and anthracycline-resistant sublines of P388 leukemia.
    Inaba M; Johnson RK
    Biochem Pharmacol; 1978; 27(17):2123-30. PubMed ID: 31880
    [No Abstract]   [Full Text] [Related]  

  • 18. Cellular accumulation and disposition of aclacinomycin A.
    Egorin MJ; Clawson RE; Ross LA; Schlossberger NM; Bachur NR
    Cancer Res; 1979 Nov; 39(11):4396-400. PubMed ID: 498071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular pharmacokinetics of aclacinomycin A in cultured L1210 cells. Comparison with daunorubicin and doxorubicin.
    Zenebergh A; Baurain R; Trouet A
    Cancer Chemother Pharmacol; 1982; 8(2):243-9. PubMed ID: 6955072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia.
    Johnson RK; Chitnis MP; Embrey WM; Gregory EB
    Cancer Treat Rep; 1978 Oct; 62(10):1535-47. PubMed ID: 709555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.